GlassScriptPhysician profile
Layth Al-Jashaami
NPI 1255691895
$13,416.78
in general payments reported to CMS, 2019-2025
44 companies · $3,336 in 2025
The $3,336 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $184 · 2021: $879 · 2022: $2,030 · 2023: $3,800 · 2024: $2,399 · 2025: $3,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,534.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,952.31 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $798.56 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $740.27 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $642.39 | 2019-2025 | Trulance, Xifaxan |
| Genzyme Corporation | $584.46 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $427.05 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $345.47 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $340.30 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $332.73 | 2022-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $323.68 | 2024-2025 | Iqirvo |
| Conmed Corporation | $289.93 | 2019 | |
| Pfizer INC. | $289.71 | 2022-2025 | |
| Celgene Corporation | $285.95 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $262.16 | 2023 | |
| Janssen Biotech, INC. | $255.34 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $247.09 | 2020-2025 | Tremfya |
| Lilly USA, LLC | $188.02 | 2025 | Omvoh |
| Boston Scientific Corporation | $183.15 | 2019-2024 | Apollo Esg System |
| Celltrion USA INC. | $174.89 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $161.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $160.38 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $135.60 | 2022-2025 | Ibsrela |
| Merit Medical Systems INC | $131.63 | 2025 | Esophyx |
| Apollo Endosurgery US INC | $124.46 | 2021 | |
| Ferring Pharmaceuticals INC. | $123.07 | 2021-2023 | Cimzia, Clenpiq, Rebyota |
| Merck Sharp & Dohme LLC | $116.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $112.62 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $106.67 | 2024 | Dupixent |
| Qol Medical, LLC | $97.75 | 2025 | Sucraid |
| Mylan Institutional INC. | $71.51 | 2023 | Hulio |
| Aimmune Therapeutics, INC. | $63.80 | 2025 | Vowst |
| Medtronic, INC. | $63.66 | 2021-2024 | Interstim |
| Biocon Biologics INC | $45.01 | 2024-2025 | Yesintek, Hulio |
| Capsovision, INC. | $34.23 | 2023 | Capsocam Plus |
| Fresenius Kabi USA, LLC | $31.37 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $25.72 | 2023 | Givlaari |
| Abbott Laboratories | $22.32 | 2024 | Proclaim |
| Intuitive Surgical, INC. | $21.97 | 2023 | Da Vinci Surgical System |
| Lucid Diagnostics INC. | $20.87 | 2025 | |
| Daiichi Sankyo INC. | $18.78 | 2023 | Injectafer |
| Organon LLC | $18.49 | 2023 | Hadlima |
| Exact Sciences Corporation | $17.45 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.89 | 2023 | Cyltezo |
| Intra-Sana Laboratories | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layth Al-Jashaami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.